SCHEMBL27244993

SCHEMBL27244993

CC(C)C[C@@H](C(=O)O)N(C)C(=O)[C@H](C)N

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.47
SLC1A3 P43003 3/20 0.41
SLC1A2 P43004 3/20 0.41
SLC1A1 P43005 2/20 0.39
RNPEP Q9H4A4 1/20 0.38
CPA1 P15085 1/20 0.35
LAP3 P28838 3/20 0.35
ANPEP P15144 1/20 0.35
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
CACNA2D1 P54289 2/20 0.33
CACNB3 P54284 1/20 0.33
CACNA1C Q13936 1/20 0.33
ENPEP Q07075 1/20 0.33
PGR P06401 1/20 0.33
ADRA1A P35348 1/20 0.33
HTR2B P41595 1/20 0.33
CACNA2D2 Q9NY47 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27244999 1.00 SLC7A5 (0.47) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
Trifluoroacetic Acid SCHEMBL30890611 0.90 SLC7A5 (0.39) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
Trifluoroacetic Acid SCHEMBL27244741 0.90 SLC7A5 (0.39) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
SCHEMBL3124635 0.85 SLC7A5 (0.44) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
SCHEMBL14161358 0.80 MMP9 (0.36) SLC7A5SLC1A3SLC1A2ANPEPMMP2
SCHEMBL18125957 0.79 RNPEP (0.43) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
SCHEMBL23182436 0.78 RNPEP (0.46) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
SCHEMBL11161410 0.78 RNPEP (0.46) SLC7A5SLC1A3SLC1A2SLC1A1RNPEP
SCHEMBL27245113 0.77 SLC7A5 (0.41) SLC7A5SLC1A3SLC1A2SLC1A1CPA1
SCHEMBL27245118 0.77 SLC7A5 (0.41) SLC7A5SLC1A3SLC1A2SLC1A1CPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 EP disclosed
US-20240199647-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-20 US disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 WO disclosed
EP-4269422-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199647-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 SLC7A5 2007/4885SLC1A3 3674/4885SLC1A2 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.